GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » PS Ratio

VRCDF (Verici Dx) PS Ratio : 1.43 (As of Mar. 27, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Verici Dx PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Verici Dx's share price is $0.03. Verici Dx's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was $0.02. Hence, Verici Dx's PS Ratio for today is 1.43.

Good Sign:

Verici Dx PLC stock PS Ratio (=5.25) is close to 2-year low of 5.25

The historical rank and industry rank for Verici Dx's PS Ratio or its related term are showing as below:

VRCDF' s PS Ratio Range Over the Past 10 Years
Min: 1.54   Med: 13.5   Max: 22.5
Current: 1.54

During the past 4 years, Verici Dx's highest PS Ratio was 22.50. The lowest was 1.54. And the median was 13.50.

VRCDF's PS Ratio is ranked better than
69.34% of 212 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.815 vs VRCDF: 1.54

Verici Dx's Revenue per Sharefor the six months ended in Jun. 2024 was $0.02. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was $0.02.

Back to Basics: PS Ratio


Verici Dx PS Ratio Historical Data

The historical data trend for Verici Dx's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx PS Ratio Chart

Verici Dx Annual Data
Trend Dec20 Dec21 Dec22 Dec23
PS Ratio
- - - 19.50

Verici Dx Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
PS Ratio Get a 7-Day Free Trial - - - 19.50 -

Competitive Comparison of Verici Dx's PS Ratio

For the Diagnostics & Research subindustry, Verici Dx's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Verici Dx's PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's PS Ratio distribution charts can be found below:

* The bar in red indicates where Verici Dx's PS Ratio falls into.


';

Verici Dx PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Verici Dx's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.03/0.021
=1.43

Verici Dx's Share Price of today is $0.03.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Verici Dx's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was $0.02.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Verici Dx  (OTCPK:VRCDF) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Verici Dx PS Ratio Related Terms

Thank you for viewing the detailed overview of Verici Dx's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Verici Dx Business Description

Traded in Other Exchanges
Address
19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies that will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx Headlines

No Headlines